Only 1.5% of Africa’s population is fully vaccinated against COVID-19, but according to a recent FiercePharma article, that number is about to go up drastically. The U.S. is investing $200 million in an Aspen Pharmacare manufacturing facility in South Africa to boost the production of the Johnson & Johnson vaccine. The funds will allow the plant to increase capacity far beyond its current rate of 300 million doses per year. J&J has gone on record as saying it is providing its vaccine on a “not-for-profit basis” during the global pandemic, and pledged 500 million doses to the COVAX worldwide relief initiative last December.
U.S. Gives $200M to Boost Vaccines in Africa
The investment will increase production capacity of the J&J vaccine beyond its current rate of 300 million doses per year.
Jul 30, 2021
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
